display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - PDL1 positive
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone IMpower-110 ... IMpower-110 ... IMpower-110 ...
cemiplimab EMPOWER lung1 ...
durvalumab based treatment
durvalumab alone MYSTIC ...
nivolumab based treatment
nivolumab alone CheckMate 026 ... CheckMate 026 ...
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-042 ... KEYNOTE-042 ... KEYNOTE-024 ... KEYNOTE-042 ...
Immune checkpoint association
durvalumab plus tremelimumab MYSTIC ...
nivolumab plus ipilimumab CheckMate 227 ...
pembrolizumab plus ipilimumab KEYNOTE-598

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons